A Phase 2/3 Multi-center Study to Evaluate the Safety and Efficacy of Blinatumomab in Subjects With Relapsed/Refractory Aggressive B-Cell Non Hodgkin Lymphoma
Phase of Trial: Phase II/III
Latest Information Update: 11 Oct 2017
At a glance
- Drugs Blinatumomab (Primary)
- Indications Diffuse large B cell lymphoma; Follicular lymphoma; Non-Hodgkin's lymphoma
- Focus Therapeutic Use
- Sponsors Amgen
- 06 Oct 2017 Planned End Date changed from 25 Oct 2020 to 1 Jan 2021.
- 06 Oct 2017 Planned primary completion date changed from 27 Jul 2020 to 3 Oct 2020.
- 10 Jun 2017 Biomarkers information updated